The slight decrease in price target by Oppenheimer reflects a minor adjustment in valuation expectations for Cytokinetics. Given the Outperform rating is maintained, the impact on the stock is likely neutral in the short term, as the adjustment is minimal and the overall bullish stance remains unchanged.